SERUM PROGRAMMED CELL DEATH PROTEIN 5 (PDCD5) LEVELS IS UPREGULATED IN LIVER DISEASES

SERUM PROGRAMMED CELL DEATH PROTEIN 5 (PDCD5) LEVELS IS UPREGULATED IN LIVER DISEASES
复制标题

DOI:
10.1080/15321819.2012.731461
复制
发表时间:
2013-07-03
影响因子:
--
通讯作者:
Jin, Lei
Jin, Lei
中科院分区:
其他
文献类型:
--
作者:
Chen, Yingyu;Zou, Zhiqiang;Jin, Lei

文献摘要

被引文献

相似文献

受损细胞释放后,在血液中检测到细胞内蛋白质分子。 PDCD5在大多数类型的正常人体组织中广泛表达,并且在正在凋亡的细胞中不受调节。因此推测 PDCD5 释放到循环中可能是细胞凋亡的特异性标志物。在本研究中,开发了一种夹心 ELISA,用于定量可溶性 PDCD5 蛋白,并用于研究肝脏疾病中的血清 PDCD5 水平。与正常受试者和其他检测到的肝脏疾病(例如慢性活动性乙型肝炎(CAHB)、慢性持续性乙型肝炎(CPHB)和肝硬化(LC))相比,急性黄疸型肝炎(AIH)患者中检测到的PDCD5水平最高。 AIH 和 CAHB 患者中 PDCD5 水平升高与 ALT 和 AST 密切相关。在 CPHB 患者中,PDCD5 水平升高与 AST、TBI、DBIL 和 IBIL 密切相关。在 LC 患者中,PDCD5 水平与 AST/ALT 和 DBIL 密切相关。更重要的是,在 ALT 或 AST 水平正常的患者中也观察到 PDCD5 水平升高。这些数据证明了血清中 PDCD5 水平升高与肝脏疾病进展之间的相关性,并表明血清 PDCD5 作为监测肝损伤的生物标志物的潜在用途。
Intracellular protein molecules are detected in the blood following release from damaged cells. PDCD5 is widely expressed in most types of normal human tissue and is unregulated in cells undergoing apoptosis. It is therefore hypothesized that release of PDCD5 into the circulation might be a specific marker of apoptosis. In this study, a sandwich ELISA was developed for quantification of soluble PDCD5 protein and used to investigate serum PDCD5 levels in liver diseases. The highest levels of PDCD5 were detected in acute icteric hepatitis (AIH) patients compared with normal subjects and other detected liver diseases, such as chronic active hepatitis B (CAHB), chronic persistent hepatitis B (CPHB) and and liver cirrhosis (LC). Increased PDCD5 levels correlated well with ALT and AST in AIH and CAHB patients. In patients with CPHB, increased PDCD5 levels correlated well with AST, TBI, DBIL, and IBIL. In LC patients, PDCD5 levels correlated well with AST/ALT and DBIL. More importantly, increased PDCD5 levels were also observed in patients with normal ALT or AST levels. These data demonstrate a correlation between increased levels of PDCD5 in serum and liver disease progression and indicate the potential utility of serum PDCD5 as a biomarker for monitoring liver injury.